Education
About Us
Working with TipRanks
Follow Us
Checkpoint Therapeutics Inc (CKPT)
NASDAQ:CKPT
Total Valuation
Checkpoint Therapeutics has a market cap or net worth of $335.89M. The enterprise value is $167.29M.
Market Cap$335.89M
Enterprise Value$167.29M
Share Statistics
Checkpoint Therapeutics has 83.06M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding83.06M
Owned by Insiders14.66%
Owned by Instutions0.10%
Financial Efficiency
Checkpoint Therapeutics’s return on equity (ROE) is 4.45 and return on invested capital (ROIC) is 444.94%.
Return on Equity (ROE)445.47%
Return on Assets (ROA)-752.78%
Return on Invested Capital (ROIC)444.94%
Return on Capital Employed (ROCE)444.94%
Revenue Per Employee$1,958.333
Profits Per Employee-$1,936,166.667
Employee Count24
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Checkpoint Therapeutics is -2.26. Checkpoint Therapeutics’s PEG ratio is 0.05.
PE Ratio-2.26
PS Ratio0.00
PB Ratio-10.06
Price to Fair Value-10.06
Price to FCF-4.08
Price to Operating Cash Flow-4.08
PEG Ratio0.05
Income Statement
In the last 12 months, Checkpoint Therapeutics had revenue of $47.00K and earned -$46.47M in profits. Earnings per share was -$1.44.
Revenue$47.00K
Gross Profit-$21.23M
Operating Income-$37.51M
Pretax Income-$46.47M
Net Income-$46.47M
EBITDA-37.51M
Earnings Per Share (EPS)-1.44
Cash Flow
In the last 12 months, operating cash flow was -$30.76M and capital expenditures $0.00, giving a free cash flow of -$30.76M billion.
Operating Cash Flow-$30.76M
Free Cash Flow-$30.76M
Free Cash Flow per Share-$0.37
Dividends & Yields
Checkpoint Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-24.50%
Earnings Yield-44.30%
Stock Price Statistics
Beta0.71
52-Week Price Change137.87%
50-Day Moving Average3.56
200-Day Moving Average3.05
Relative Strength Index (RSI)62.41
Average Volume (3m)4.59M
Important Dates
Checkpoint Therapeutics upcoming earnings date is May 8, 2025, TBA.
Last Earnings DateMar 28, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Checkpoint Therapeutics as a current ratio of 0.37, with Debt / Equity ratio of 0.00
Current Ratio0.37
Quick Ratio0.37
Debt to Market Cap0.00
Net Debt to EBITDA0.12
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Checkpoint Therapeutics has paid $15.30M in taxes.
Income Tax$15.30M
Effective Tax Rate0.00%
Enterprise Valuation
Checkpoint Therapeutics EV to EBITDA ratio is -2.14, with an EV/FCF ratio of -3.87.
EV to Sales0.00
EV to EBITDA-2.14
EV to Free Cash Flow-3.87
EV to Operating Cash Flow-3.87
Balance Sheet
Checkpoint Therapeutics has $4.70M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$4.70M billion.
Cash & Marketable Securities$4.70M
Total Debt$0.00
Net Cash-$4.70M
Net Cash Per Share-$0.06
Tangible Book Value Per Share-$0.32
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Checkpoint Therapeutics is $5.30, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.30
Price Target Upside31.84%
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-60.19%
EPS Growth Forecast56.60%